MedTrace Logo

Pilot Study of Diflunisal in HIV-infected Adults

NCT01676363 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-10-27

No results posted yet for this study

Summary

Diflunisal is an anti-inflammatory drug (like ASA or ibuprofen) that has been used as a painkiller for 20 years. Recent research shows that it may have an anti-HIV effect in the laboratory. Approximately 20 HIV-infected adults who are not receiving antiretroviral therapy will be given diflunisal by mouth twice daily for 4 weeks, at a dose that has been shown to be safe when used to treat pain. Subjects will be monitored closely for safety and will have frequent blood tests during the study to see if the drug has any effect on the level of HIV in their blood.

Conditions

  • HIV Infection

Interventions

DRUG

Diflunisal

Open-label diflunisal 500 mg twice daily for 4 weeks

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Julio Montaner, MD · Providence Health Care/ University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-10-12
Completion
2016-10-12

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01676363 on ClinicalTrials.gov